Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus.
The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice.